RPTX
Repare Therapeutics Inc.
$1.84
+$0.07(+3.95%)
60
Overall
80
Value
41
Tech
--
Quality
Market Cap
$76.90M
Volume
48.05K
52W Range
$0.89 - $4.07
Target Price
$5.00
Order:
Income Statement
| Metric | Trend | Chart | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Total Revenue | -- | -- | $131.8M | $51.1M | $53.5M | ||
| Total Revenue | -- | -- | $131.8M | $51.1M | $53.5M | ||
| GROSS PROFIT | |||||||
| Gross Profit | -- | -- | -- | $51.1M | -- | ||
| OPERATING EXPENSES | |||||||
| Operating Expenses | $54.4M | $116.3M | $151.6M | $167.4M | $147.0M | ||
| Research & Development | $40.1M | $90.0M | $119.1M | $133.6M | $115.9M | ||
| Research Expense | $40.1M | $90.0M | $119.1M | $133.6M | $115.9M | ||
| Selling, General & Administrative | $14.3M | $26.2M | $32.6M | $33.8M | $29.7M | ||
| General & Administrative Expenses | $14.3M | $26.2M | $32.6M | $33.8M | $29.7M | ||
| Salaries & Wages | $-135.0K | $-7.6M | $-131.8M | $25.1M | $23.2M | ||
| Depreciation & Amortization | $897.0K | $1.5M | $2.0M | $2.0M | $1.9M | ||
| Depreciation & Amortization | $897.0K | $1.5M | $2.0M | $2.0M | $1.9M | ||
| Other Operating Expenses | $1.2M | -- | $2.8M | $2.7M | -- | ||
| OPERATING INCOME | |||||||
| Operating income | $-54.3M | $-108.7M | $-19.8M | $-116.2M | $-93.5M | ||
| EBITDA | $-53.4M | $-107.2M | $-17.8M | $-114.3M | $-79.0M | ||
| NON-OPERATING ITEMS | |||||||
| Intinc | $240.0K | -- | -- | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $240.0K | -- | $-5.6M | $-13.3M | -- | ||
| Gain on Sale of Securities | $240.0K | $259.0K | $5.6M | $13.3M | $10.4M | ||
| Other Income/Expense | $-224.0K | $-218.0K | $265.0K | $-13.2M | $-10.3M | ||
| Other Special Charges | $-16.0K | $-41.0K | $-43.0K | $-119.0K | $-115.0K | ||
| SPECIAL ITEMS | |||||||
| Restructring And Mn A Income | -- | -- | -- | -- | $1.4M | ||
| Special Income Charges | -- | -- | -- | -- | $-1.4M | ||
| PRE-TAX INCOME | |||||||
| EBIT | $-54.3M | $-108.7M | $-19.8M | $-116.2M | $-83.2M | ||
| Pre-Tax Income | $-54.7M | $-108.6M | $-13.9M | $-103.2M | $-83.2M | ||
| INCOME TAX | |||||||
| Tax Provision | $-1.3M | $-1.7M | $15.1M | $-9.4M | $1.4M | ||
| NET INCOME | |||||||
| Net Income | $-53.4M | $-106.9M | $-29.0M | $-93.8M | $-84.7M | ||
| Net Income (Continuing Operations) | $-53.4M | $-106.9M | $-29.0M | $-93.8M | $-84.7M | ||
| Net Income (Discontinued Operations) | $-53.4M | $-106.9M | $-29.0M | $-93.8M | $-84.7M | ||
| Net Income (Common Stockholders) | $-53.4M | $-106.9M | $-29.0M | $-93.8M | $-84.7M | ||
| Normalized Income | -- | $-110.3M | -- | -- | $-81.0M | ||
| TOTALS | |||||||
| Total Expenses | $54.4M | $116.3M | $151.6M | $167.4M | $147.0M | ||
| SHARE & EPS DATA | |||||||
| Average Shares Outstanding | $20.0M | $37.8M | $41.9M | $42.1M | $42.4M | ||
| Average Shares Outstanding (Diluted) | $20.0M | -- | $41.9M | $42.1M | $42.4M | ||
| Shares Outstanding | $36.9M | $41.9M | $42.1M | $42.2M | $42.5M | ||
| Basic EPS | $-2.66 | $-2.83 | $-0.69 | $-2.23 | $-2 | ||
| Basic EPS (Continuing Operations) | $-2.66 | $-2.83 | $-0.69 | $-2.23 | $-2 | ||
| Diluted EPS | $-2.66 | $-2.83 | $-0.69 | $-2.23 | $-2 | ||
| Diluted EPS (Continuing Operations) | -- | -- | $-0.69 | $-2.23 | $-2 | ||
| OTHER METRICS | |||||||
| Other Gand A | $14.3M | $26.2M | $32.6M | $33.8M | $29.7M | ||
| Restruct | -- | -- | -- | -- | $1.4M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RPTX | $1.84 | +4.0% | 48.05K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Repare Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW